Getting guidelines correct: Their evidence-based recommendations for use of nonstatins added to statins and the need for follow-up lipid testing

Journal of the American College of Cardiology

Volumn 65, Issue 18, 2015, Pages 2051-2052

  Stone, Neil J ^a   Bairey Merz, C Noel ^b   Watson, Karol E ^b   Smith, Sidney C ^b  

^a Northwestern Medicine ^*  (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID;

ACUTE CORONARY SYNDROME; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG SAFETY; EVIDENCE BASED MEDICINE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LETTER; LIPID ANALYSIS; PATIENT PREFERENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; BLOOD; FEMALE; HYPERCHOLESTEROLEMIA; MALE;

CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; PRACTICE GUIDELINES AS TOPIC;

EID: 84928963614     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.12.072     Document Type: Letter

References (5)

1. T.M. Maddox, W.B. Borden, and F. Tang Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE Registry J Am Coll Cardiol 64 2014 2183 2192
2. N.J. Stone, J.G. Robinson, and A.H. Lichtenstein 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2014 2889 2934
3. The AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy [erratum, N Engl J Med 2012;367:189] N Engl J Med 365 2011 2255 2267
4. HPS-2 THRIVE Collaborative Group HPS2-THRIVE randomized placebo-controlled trial in 25,673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J 34 2013 1279 1291
5. M.A. Blazing, R.P. Giugliano, and C.P. Cannon Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population Am Heart J 168 2014 205 212.e1